MAB15981-100

antibody from R&D Systems

Targeting: IFNL1 IL-29, IL29

ELISA (Data presented on provider website)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

MAB15981-100

Provider

R&D Systems

Product name

Human IL-29/IFN-lambda 1 Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from hybridoma culture supernatant. Detects human IL-29/IFN-lambda 1 in ELISAs. In sandwich immunoassays, 100% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and 20% with rhIL-28A is observed. No cross-reactivity or interference was observed with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN-alpha I, or rhIFN-beta 1A.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

Q8IU54


Isotype

IgG

Antibody clone number

247801

Vial size

100 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.

Oke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, Svenungsson E
Arthritis research & therapy 2019 Apr 29;21(1):107

---

Interferon (IFN)-λ is a potential mediator in lupus nephritis.

Zickert A, Oke V, Parodis I, Svenungsson E, Sundström Y, Gunnarsson I
Lupus science & medicine 2016;3(1):e000170

---

Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Villenave R, Broadbent L, Douglas I, Lyons JD, Coyle PV, Teng MN, Tripp RA, Heaney LG, Shields MD, Power UF
Journal of virology 2015 Dec;89(24):12309-18

---

Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation.

Persson BD, Jaffe AB, Fearns R, Danahay H
PloS one 2014;9(7):e102368

---

Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection.

Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, Gale M Jr, Liang TJ, Polyak SJ
Journal of virology 2014 Feb;88(3):1582-90

---

Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells.

Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, Gale M Jr, Rosen HR
PLoS pathogens 2013;9(4):e1003316

---

Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells.

Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute SB, Garrigues U, Doyle S, Donnelly RP, Kotenko SV, Fitzgerald-Bocarsly P
Journal of immunology (Baltimore, Md. : 1950) 2012 Sep 15;189(6):2735-45

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

IL-29/IFN-lambda 1 Inhibition of EMCV-induced Cytopathy and Neutralization by Human IL-29/IFN-lambda 1 Antibody. Recombinant Human IL-29/IFN-lambda 1 (Catalog # 1598-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-29/IFN-lambda 1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anri-Human IL-29/IFN-lambda 1 Monoclonal Antibody (Catalog # MAB15981). The ND₅₀ is typically 1-4 µg/mL.